Keyword: Samsung Bioepis

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.

Biogen is putting down $100 million upfront for copycats to Roche's Lucentis, Regeneron's Eylea and new rights for anti-TNF drugs in China.

FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.

Samsung Bioepis wins FDA nod for a Humira biosim; Celltrion forms Chinese biosim joint venture; GenScript debuts a clinical biologics plant.

Hansoh and Hengrui chiefs together make one of biopharma's richest families; prosecutors grill top Samsung exec; FDA cites another Aurobindo plant.

With a new FDA nod in postsurgery patients—and Herceptin biosimilars looming—Roche's Kadcyla has more space to run.

Samsung BioLogics has faced scrutiny of a biosimilars joint venture. Now, officials are looking more closely into the company's 2016 public listing.

Biologics CDMO Samsung BioLogics has kept up its frantic growth even as it deals with legal issues tied to its joint venture with Biogen.

The European exodus from branded Humira to biosimilars confirms that AbbVie was was way too optimistic about sales erosion, a Bernstein report reveals.